Needham & Company Starts Neurocrine Bio. (NBIX) at Buy
Get Alerts NBIX Hot Sheet
Rating Summary:
24 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 14 | New: 22
Join SI Premium – FREE
Needham & Company initiates coverage on Neurocrine Bio. (NASDAQ: NBIX) with a Buy rating and a price target of $62.00.
Analyst Alan Carr commented, "We are initiating coverage of Neurocrine with a BUY rating. Neurocrine announced positive results from a Phase 3 trial of Ingrezza in Tardive Dyskinesia (TD) in 2015. We expect approval by 4/11/17 PDUFA date, followed by launch with a specialty sales force. We have a bias toward positive Phase 2 outcome in Tourette Syndrome (TS) based on prior clinical data, and we assume label expansion 2020. We estimate US peak sales $1.6B. Collaborator Abbvie announced postive Phase 3 results in Endometriosis and guided for NDA submission 2H17. Phase 3 trials in Uterine Fibroids are underway and we are optimistic based on encouraging Phase 2 data. We estimate WW peak sales $3B. Our $62 PT is 25x $4.46 2021E EPS, discounted 15% annually. We believe there is near-term room for upside around Ingrezza Phase 2 TS data and 2Q17 TD approval."
For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.
Shares of Neurocrine Bio. closed at $42.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Applied Blockchain Inc (APLD) PT Lowered to $13 at Needham
- SharkNinja (SN) selling shareholders to offer ~4.7M shares
- Ascendis Pharma (ASND) PT Raised to $260 at Wells Fargo
Create E-mail Alert Related Categories
Analyst Comments, Hot New Coverage, New CoverageRelated Entities
Needham & Company, PDUFA, Alan CarrSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!